eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 17
Image in intervention

Transcatheter aortic valve implantation in moderate bicuspid aortic valve disease in a patient with end-stage dilated cardiomyopathy – bridge to heart transplantation

Magdalena Mizia-Szubryt
Damian Hudziak
Marek Grabka
Justyna Małyszek-Tumidajewicz
Wojciech Wojakowski
Katarzyna Mizia-Stec

First Department of Cardiology, Medical University of Silesia, Katowice, Poland
Department of Cardiac Surgery, Medical University of Silesia, Katowice, Poland
Department of Cardiac Surgery and Transplantology, Silesian Center for Heart Diseases, Faculty of Medicine in Zabrze, Medical University of Silesia in Katowice, Poland
Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
Adv Interv Cardiol 2021; 17, 4 (66): 427–428
Online publish date: 2021/11/17
Article file
- Transcatheter aortic.pdf  [0.12 MB]
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero

A 64-year-old patient with dilated cardiomyopathy (DCM) and chronic heart failure with reduced ejection fraction (HFrEF), with an implanted cardioverter-defibrillator, was admitted to the cardiology unit due to consecutive acute heart failure (HF) decompensation. Regardless of potent optimal pharmacotherapy, at admission, the patient was in NYHA class 4.

Transthoracic echocardiography (TTE) revealed severe dilatation with significantly reduced left ventricle (LV) systolic function (EF LV – 10%). A combined aortic valve (AV) disease in the form of moderate stenosis and regurgitation was revealed. Morphologically aortic leaflets were calcified, peak velocity in continuous wave (CW) was V max. 1.8 m/s, in colour Doppler (CD) the width of the valve insufficiency – jet 8 mm, the width of the left ventricular outflow tract (LVOT) – 19 mm, pressure half time (PHT) 380 ms. Transesophageal echocardiography (TEE) confirmed the presence of a complex AV defect (AVA planimetric – 1.5 cm2, AR – jet 8 mm, LVOT – 18 mm, EDV in descending aorta – 20 cm/s) (Figure 1). The evaluation of AV morphology revealed a bicuspid AV (BAV): fusion of the right coronary cusp (RCC) and the left coronary cusp (LCC) – fusion flap: still and calcified.

Figure 1

Transesophageal echocardiography: A – AVA planimetric in 3D reconstruction (AVA – 1.52 cm2), B – aortic regurgitation in TEE (jet AR – 8 mm, LVOT – 18 mm), C, D – valve prosthesis Edwards-Sapien 3 Ultra (29) – after procedure TAVI in TEE (long axis view – C), (short axis view – D)


Due to the worsening of clinical status and signs of LV low output, the pharmacotherapy was intensified. To qualify the patient for heart transplantation (HTX)/biventricular support, right heart catheterization (RHC) was performed. Based on RHC results (mPAP – 48 mm Hg, PVR – 6.85 Wood units, CO – 2.48 l/min, CI – 1.1 l/min/m2) precapillary pulmonary hypertension (PH) was diagnosed. It was a reason for the patient’s disqualification from HTX.

Considering the coexisting complex BAV pathology, the patient was consulted by the Heart Team – due to the significant risk of death (EUROSCORE II – 8.2%), he was disqualified from the classical aortic valve replacement and was qualified for transcatheter aortic valve implantation (TAVI) as a life-saving procedure.

The procedure was performed under local anaesthesia by the multidisciplinary TAVI team. A balloon-expandable valve prosthesis Edwards-Sapien 3 Ultra (29) (Edwards Lifesciences Corp., Irvine, CA, USA) was implanted. The result was satisfactory (implantation depth correct, no occlusion of coronary arteries, no tamponade and no paravalvular leak).

After the TAVI, the patient was significantly improved, which allowed the intravenous treatment to be stopped and the HF standard pharmacotherapy to be optimized. TTE showed normal aortic prosthesis function, regression of LV volume (EDV from 341 ml to 290 ml) with persistently reduced LV systolic function (LVEF 17%). Laboratory tests showed a significant decrease in NT-pro BNP, and normalization of hepatic and renal parameters. The follow-up RHC confirmed significant regression of PH indices (mPAP – 35 mm Hg, PVR – 4.0 Wood units, CO – 3.83 l/min, CI 1.82 l/min/m2), and finally, he was qualified for HTX. Currently, he is in a stable state, waiting for further proceedings.

Currently, the indications for TAVI are increasing (AHA 2020); however, standard TAVI procedures are indicated for high-risk patients with severe symptomatic aortic stenosis.

We present successful, nonstandard use of this method in end-stage HF in the case of DCM and moderate BAV disease. Normalization of AV function due to the TAVI procedure allowed for PH regression and constituted a bridge to HTX [13].

Conflict of interest

The authors declare no conflict of interest.



Bastos MB, Schreuder JJ, Daemen J, Van Mieghem NM , authors. Hemodynamic effects of transcatheter aortic valve replacement for moderate aortic stenosis with reduced left ventricular ejection fraction. JACC Cardiovasc Interv. 2019. 12:p. 684–6


Fried JA, Nazif TM, Colombo PC , authors. A new frontier for TAVR: aortic insufficiency in CF-LVAD patients. J Heart Lung Transplant. 2019. 38:p. 927–9


Edelman JJ, Khan JM, Rogers T, et al. , authors. Valve-in-Valve TAVR: state-of-the-art review. Innovations. 2019. 14:p. 299–310

Copyright: © 2021 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.